70 Gy radiotherapy to the prostate, seminal vesicles and whole pelvis when combined with 3 years of hormones improves overall and disease specific survival compared with radiotherapy on its own
This landmark study compared 2 treatment groups in 415 men with locally advanced (mostly T3N0M0) prostate cancer. Both groups received 70 Gy to the prostate, seminal vesicles and whole pelvis as primary radiotherapy while only one group received goserelin hormones concurrently for 3 years. The combined radiotherapy plus 3 year hormone group did much better. The combined treatment resulted in 5 year overall survival benefit (79% overall survival v 62%) and a disease free survival benefit of 85% v 48%.